Stock PAX PAXMAN AB
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Paxman AB

Equities

PAX

SE0009806284

Market Closed - Nasdaq Stockholm
Other stock markets
 12:00:00 2024-06-27 EDT 		5-day change 1st Jan Change
46.2 SEK +0.87% Intraday chart for Paxman AB +2.67% +25.54%
05-23 Paxman AB Appoints Karen Giddings Clakely to the Board CI
05-23 Paxman AB Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • According to Refinitiv, the company's ESG score for its industry is poor.

Strengths

  • The prospective high growth for the next fiscal years is among the main assets of the company
  • The earnings growth currently anticipated by analysts for the coming years is particularly strong.
  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • The group's high margin levels account for strong profits.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Medical Equipment, Supplies & Distribution

1st Jan change Capi. Investor Rating ESG Refinitiv
PAXMAN AB Stock Paxman AB
+25.54% 82.41M
D
ABBOTT LABORATORIES Stock Abbott Laboratories
-4.64% 182B
C+
MEDTRONIC PLC Stock Medtronic plc
-3.99% 103B
C
BECTON, DICKINSON AND COMPANY Stock Becton, Dickinson and Company
-5.22% 66.94B
A
CENCORA, INC. Stock Cencora, Inc.
+9.49% 46.73B
B-
DEXCOM, INC. Stock DexCom, Inc.
-8.22% 45.14B
B-
HOYA CORPORATION Stock Hoya Corporation
+5.82% 41.57B
B+
METTLER-TOLEDO INTERNATIONAL, INC. Stock Mettler-Toledo International, Inc.
+17.37% 30.48B
B
TERUMO CORPORATION Stock Terumo Corporation
+14.00% 24.26B
A-
WEST PHARMACEUTICAL SERVICES, INC. Stock West Pharmaceutical Services, Inc.
-5.65% 23.58B
A-
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy
  1. Stock Market
  2. Equities
  3. PAX Stock
  4. Ratings Paxman AB